Methods of synthesis
How were the studies combined? A narrative synthesis was undertaken.
How were differences between studies investigated?
Details of the individual studies were tabulated and were presented in the text, according to the type of pain being treated.
Results of the review
Nine RCTs were included in the review. The number of participants was unclear.
Cancer pain. In the 5 trials on cancer pain, 128 patients (figure derived from the table) were studied. In one study, 2 to 4 mg oral BPP (a THC congener) was not as effective as codeine sulphate (60 to 120 mg), and was no more effective than placebo in 37 patients. Oral THC (5 to 20 mg) was found to have an analgesic effect when compared with placebo in 10 patients with pain related to advanced cancer. In this study, a dose-response relationship was shown for analgesia but also for adverse effects. In a further study by the same group, oral THC 10 mg was approximately equipotent to codeine 60 mg, and THC 20 mg was approximately equipotent to codeine 120 mg. The higher dose was associated with unacceptable adverse effects. In one trial, NIB given orally was superior to placebo and equivalent to approximately 50 mg of codeine phosphate. In a second study in the same report, this nitrogen analogue was found to be superior to placebo and to 50 mg of secobarbital. However, in both of these trials NIB was felt to be of no clinical use, because of the frequency of the adverse effects.
Chronic non-malignant pain.
Two patients were studied in 2 'n of 1 within patient crossover' trials for 6 weeks and 5 months, respectively. In an experienced cannabis user with familial Mediterranean fever, THC was found to be no better than placebo in terms of visual analogue scores for pain intensity. However, the level of morphine used for breakthrough pain was significantly lower while the patient was taking THC than when taking placebo: 170 mg versus 410 mg per 3 weeks. In a patient with neuropathic pain and spasticity secondary to a spinal cord ependymoma, THC 5 mg and codeine 50 mg were equianalgesic, and both were superior to placebo. Only THC, however, had a beneficial effect on spasticity.
Post-operative pain.
Thirty-six patients (figure derived from the table) were studied in 2 trials (conducted as a two-phase study). Levonantradol was more effective than placebo when given intramuscularly to patients with post-operative pain. Adverse effects with levonantradol were common, although considered mild.
Cannabinoids and adverse effects. Adverse effects were reported in all studies. Two patients withdrew from studies owing to the adverse effects of THC. THC showed a dose-response relationship for adverse effects such as mental clouding, ataxia, dizziness, numbness, disorientation, disconnected thought, slurred speech, muscle twitching, impaired memory, dry mouth, and blurred vision. In addition, at 20 mg, THC was highly sedating in 100% of patients, thus prohibiting its use. THC 10 mg was better tolerated, but the frequency of these adverse effects was still higher than with codeine 60 or 120 mg. Twenty-three reductions in arterial blood-pressure occurred, compared with placebo, but no more than with codeine. Changes in heart rate were not significant. THC 5 mg was well tolerated in neuropathic pain and did not cause an altered state of consciousness. Levonantradol caused adverse effects in most patients, but none withdrew. NIB did not affect heart rate but caused drowsiness in 40% of patients, and was therefore deemed to be of no clinical use. BPP caused a similar degree of sedation to codeine but was ineffective as an analgesic.
Authors' conclusions
Cannabinoids are no more effective than codeine in controlling pain and have depressant effects on the central nervous system that limit their use. Their widespread introduction into clinical practice for pain management is therefore undesirable. They should not be used in acute post-operative pain. Before cannabinoids can be considered for treating spasticity and neuropathic pain, further valid RCTs are needed.
